DYAX: Dyax Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp.

DYAX 38.41

0.0%

Jan 25 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dalroi who wrote (49)	1/10/2003 3:31:07 PM
From: keokalani'nui	Read Replies (1) of 197

Stephaan Responding to your tfi/f post. I have not studied it yet, but did not dyax keep at least bulk of CAT Humira royalty, though possibly realized in lump-sum? >>In addition, CAT’s obligation to pay royalties under the 1997 Agreements to Dyax for rights with respect to Dyax’s Ladner patents on antibody products CAT develops is removed, except in relation to Humira™. CAT has options to buy out under a predetermined schedule any royalty obligation which CAT may have in respect of Humira. << Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next